Loading...
01/10 19:55
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reflects challenges in financial guidance with a reduction in EPS and increased MCR, indicating higher costs. While the revenue guidance remains unchanged, the company's competitive position is weak, and Medicaid enrollment is declining. The Q&A session reveals concerns about medical cost trends and potential downside risks. Despite some optimism in Medicaid rate adjustments and M&A opportunities, the overall sentiment suggests a negative outlook due to financial pressures and uncertainties, leading to a predicted stock price decrease of -2% to -8% over the next two weeks.
Adjusted Earnings Per Share (EPS) $1.84 for Q3 2025, which is below expectations. The full-year 2025 adjusted EPS guidance is revised to approximately $14 per share, down from the prior guidance of $19 per share. The reduction is attributed to higher medical cost trends, particularly in the Marketplace segment, which contributed to half of the EPS shortfall.
Premium Revenue $10.8 billion for Q3 2025. Full-year 2025 premium revenue is expected to be approximately $42.5 billion, slightly higher than previous guidance. The increase is due to growth in Medicaid and other segments.
Consolidated Medical Care Ratio (MCR) 92.6% for Q3 2025, reflecting a challenging medical cost environment. The full-year 2025 consolidated MCR is expected to be 91.3%, up 110 basis points from prior guidance. The increase is driven by higher medical cost trends across all segments.
Medicaid MCR 92% for Q3 2025, with a full-year 2025 guidance of 91.5%. The increase in MCR is due to higher-than-expected medical cost trends in behavioral health, pharmacy, LTSS, and inpatient care. Rate updates were insufficient to offset these trends.
Medicare MCR 93.6% for Q3 2025, with a full-year 2025 guidance of 91.3%. The higher MCR is attributed to elevated utilization among high-acuity dual populations, particularly for LTSS and high-cost drugs.
Marketplace MCR 95.6% for Q3 2025, significantly higher than expected. The full-year 2025 guidance is 89.7%. The increase is due to higher utilization and limited risk adjustment revenue offset, consistent with industry-wide trends.
Adjusted G&A Ratio 6.3% for Q3 2025, reflecting strong operating discipline. The full-year 2025 G&A ratio is expected to be approximately 6.5%.
Operating Cash Flow Outflow of $237 million for the first nine months of 2025. The outflow is due to the settlement of Medicaid risk corridors, Marketplace risk transfer payments, and timing of tax payments and government receivables.
Share Repurchase Approximately 2.8 million shares repurchased in Q3 2025 at a cost of $500 million. This was funded by temporarily increasing debt balances.
Medicaid contract wins: Significant new Medicaid contracts in Georgia and Texas, and Medicare duals growth in 5 states through recent RFP wins and MMP conversions. These are expected to contribute to the target of $46 billion of revenue in 2026.
Marketplace repricing strategy: The company is repricing its Marketplace book of business to reduce exposure and restore margins. This includes a 30% average rate increase and a 20% reduction in county footprint for 2026.
Medical cost management: Despite challenges, the company maintained a strong adjusted G&A ratio of 6.3% in Q3 2025, reflecting operational discipline.
Capital management: Harvested $278 million in subsidiary dividends and maintained a strong capital foundation with a parent company cash balance of $108 million.
Growth initiatives: The company is targeting to surpass $50 billion in premium revenue in the next few years through RFP wins and an active M&A pipeline of $54 billion in opportunities.
Marketplace rationalization: The company is reducing its Marketplace exposure by exiting difficult geographies and focusing on stabilizing the risk pool.
Medical Cost Trend: Higher-than-expected medical cost trends in Medicaid, Medicare, and Marketplace segments, driven by behavioral health, pharmacy, LTSS, and inpatient care utilization, are pressuring margins. Medicaid's medical cost trend is now expected to be 7%, exceeding rate increases of 5.5%.
Marketplace Segment Performance: The Marketplace segment significantly underperformed expectations, with a third-quarter MCR of 95.6% and a full-year trend rising from 11% to 15%. This segment is expected to produce a loss of $2 per share, contributing to half of the EPS reduction from initial guidance.
Medicare Utilization: Higher utilization among high-acuity duals populations, particularly for LTSS and high-cost pharmacy drugs, has led to a third-quarter MCR of 93.6% and breakeven pretax margins for the full year.
Rate and Trend Imbalance: Rate increases in Medicaid and Medicare have not kept pace with rising medical cost trends, leading to higher MCRs and reduced margins. States are slow to adjust rates to reflect the sustained high medical cost environment.
Regulatory and Budgetary Changes: The recently passed budget bill may impact Medicaid membership, with most effects expected in 2027 and 2028. Additionally, the lapse of enhanced tax credits in Marketplace is creating uncertainty in the risk pool.
Revenue Headwinds in 2026: The company anticipates revenue headwinds in 2026 due to repricing the Marketplace book of business to reduce exposure and restore margins, as well as potential small impacts to Medicaid membership from regulatory changes.
Capital and Cash Flow Challenges: Operating cash flow for the first nine months of 2025 was an outflow of $237 million due to Medicaid risk corridors, Marketplace risk transfer payments, and timing of tax payments and government receivables.
M&A and Growth Risks: While the company sees opportunities in M&A and RFP wins, the challenging operating environment may impact the ability to achieve target margins on acquired Medicaid revenue.
2025 Full Year Guidance: Premium revenue is expected to increase to approximately $42.5 billion. Adjusted earnings per share guidance is revised to approximately $14 per share, down from the prior guidance of $19 per share. Consolidated MCR is projected at 91.3%, with a pretax margin of 2.1%. Medicaid MCR is expected to be 91.5%, with a pretax margin of 3.2%. Medicare MCR is projected at 91.3%, with a breakeven pretax margin. Marketplace MCR is expected to be 89.7%, with a negative pretax margin. Fourth quarter EPS guidance is approximately $0.35, with Medicaid projected to earn $3 per share and Medicare and Marketplace combined expected to lose $2.65 per share.
2026 Preliminary Outlook: Premium revenue is anticipated to grow to $46 billion, driven by growth in the current footprint, new Medicaid contracts in Georgia and Texas, and Medicare duals growth in five states. Marketplace pricing strategy aims to reduce exposure, which may act as a revenue headwind but is expected to be earnings accretive. Medicaid performance in the second half of 2025 is expected to provide a strong baseline for 2026, with a projected 92.3% MCR and a 2.5% pretax margin. Early views of the January rate cycle suggest rates modestly exceeding trend. Medicare and Marketplace are projected to at least break even, with potential for margin improvement. Upside potential exists in Medicaid rate increases, Medicare margin improvements, and harvesting embedded earnings from new contracts and acquisitions.
Long-Term Growth Initiatives: The company aims to surpass $50 billion in premium revenue in the next few years. Active RFPs in several states and a $54 billion pipeline of new opportunities are expected to drive growth. The M&A pipeline includes actionable opportunities, with a focus on acquiring Medicaid revenue and improving margins. The company remains optimistic about the long-term sustainability and profitability of its Medicaid, Medicare, and Marketplace businesses.
share repurchase: In the quarter, we have repurchased approximately 2.8 million shares at a cost of $500 million. We see real value in our shares at current market prices, which we believe at this low point in the rate cycle underappreciate the longer-term margin targets of our business. Debt balances at the end of the quarter increased temporarily to fund the share repurchase.
The earnings call summary reflects challenges in financial guidance with a reduction in EPS and increased MCR, indicating higher costs. While the revenue guidance remains unchanged, the company's competitive position is weak, and Medicaid enrollment is declining. The Q&A session reveals concerns about medical cost trends and potential downside risks. Despite some optimism in Medicaid rate adjustments and M&A opportunities, the overall sentiment suggests a negative outlook due to financial pressures and uncertainties, leading to a predicted stock price decrease of -2% to -8% over the next two weeks.
The earnings call presents a mixed outlook. While there are positive aspects like strong embedded earnings, M&A focus, and maintained guidance, concerns about elevated trends, potential market enrollment decline, and unclear management responses create uncertainty. The Q&A revealed cautious optimism but highlighted risks in achieving target margins and market dynamics. Without a market cap, the stock's reaction is uncertain, but the balanced positives and negatives suggest a neutral sentiment overall.
The earnings call reflects strong financial performance with an 8% increase in EPS and robust premium revenue. The company has retained key contracts and secured new ones, supporting future growth. Share repurchases positively impact EPS guidance. While the loss of the Virginia contract and higher MCR in the marketplace pose risks, management's optimistic guidance and strategic focus on Medicaid and marketplace segments indicate resilience. The Q&A reveals confidence in Medicaid RFPs and stable rate discussions. Overall, positive sentiment is driven by growth prospects and strategic initiatives.
The earnings call highlights strong financial performance with significant growth initiatives, positive EPS and revenue guidance, and effective cost management. The Q&A section reveals management's confidence in handling MLR trends and financial forecasts, though some responses lacked clarity. Despite minor uncertainties, the overall sentiment remains optimistic, supported by solid financial metrics and strategic growth plans. The absence of negative catalysts and the potential for improved operating cash flow in 2025 further bolster a positive outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
